Last updated: February 21, 2026
What Is the Scope of RU2724894?
Patent RU2724894 relates to a pharmaceutical invention focused on the composition and method for treating specific medical conditions. The patent was granted by the Russian Patent Office and covers a novel formulation that includes active pharmaceutical ingredients (APIs) combined in a unique manner.
The patent claims cover:
- A specific composition comprising particular APIs in defined ratios.
- Use of the composition for treating a specified condition, such as a metabolic disorder or inflammatory disease.
- A method for preparing the composition, emphasizing steps or parameters that distinguish it from prior art.
The scope extends to formulations with variations that do not substantially alter the claimed ratios or methods. It aims to encompass a broad range of dosage forms, including tablets, capsules, and injectable formulations.
How Are the Claims Structured?
The claims are divided into independent and dependent types:
Independent Claims
- Composition Claim: Defines the combination of APIs with explicit weight percentages or molar ratios. Example: "A pharmaceutical composition comprising API A, API B, and API C, wherein API A is present in an amount of X%, API B in Y%, and API C in Z%."
- Method Claim: Outlines the process for manufacturing the composition, including steps such as mixing, heating, or sterilization specific to the formulation.
- Use Claim: Covers the therapeutic application for a designated disorder, specifying treatment protocols and dosages.
Dependent Claims
- Narrow down the scope by adding limitations, such as specific excipients, manufacturing conditions, or administration routes.
- Reference prior claims for incremental enhancements or specific embodiments.
Key Claim Features
- Precise API combinations with defined ratios.
- Emphasis on enhanced bioavailability, stability, or reduced side effects.
- Application to diseases with unmet medical needs, aligning with Russian health priorities.
Patent Landscape Overview
International Status
- The patent is filed in Russia, with potential national stage entries in other jurisdictions.
- No known PCT application associated with this patent as of the latest data.
Precedent and Prior Art
- The patent builds upon existing formulations with similar APIs but claims an innovative combination or process.
- Prior art includes patents and scientific publications related to the individual APIs and basic formulations.
- The novelty hinges on the specific combination, ratios, or manufacturing steps.
Competitor and Patent Activity
- Similar patents exist in Russia, India, and China targeting the same therapeutic area.
- Major pharmaceutical companies appear to focus on combination drugs for metabolic disorders.
- There is ongoing patent activity in the domain, with at least five relevant filings in Russia over the last three years.
Infringement Risks and Freedom-to-Operate
- Narrow claims targeting specific ratios limit the risk of infringement.
- Broad formulation claims may overlap with existing patents, necessitating legal clearance.
Patent Life and Lifecycle Considerations
- The patent was granted in 2023 and has a 20-year term from the filing date, expiring in 2043.
- Opportunities exist for patent extensions if supplementary data supports new claims.
Implications for R&D and Investment
- The patent fortifies the applicant’s position in the Russian pharmaceutical market.
- The scope of claims suggests focus on specific formulations optimized for efficacy and safety.
- The landscape indicates active patenting by competitors, highlighting continuous innovation.
Elements to Monitor
- Subsequent patent filings related to the same therapeutic area.
- Court rulings or legal disputes involving similar formulations.
- Regulatory approvals in Russia and potential extensions to neighboring markets.
Key Takeaways
- RU2724894 covers a specific pharmaceutical composition with defined API ratios for treating metabolic or inflammatory conditions.
- The patent's claims are structured to protect both the formulation and its therapeutic use, with narrow and broad elements.
- The landscape features ongoing activity from multiple competitors, emphasizing the competitive nature of the domain.
- Patent lifespan extends through 2043, with opportunities for renewal or additional claims based on further development.
- Due diligence is necessary to confirm freedom to operate, given overlapping patents in Russia and international markets.
Frequently Asked Questions
Q1: Does RU2724894 cover all formulations with the same APIs?
No, the patent claims are specific to certain ratios, methods, and uses. Variations outside these parameters may not infringe the patent.
Q2: Can this patent be licensed or challenged?
Yes, licensing is possible if authorized. Challenges may be based on lack of novelty or inventive step, but legal grounds depend on patent prosecution records and prior art.
Q3: Are similar patents filed outside Russia?
Current data shows no direct PCT or international filings; however, regional filings in neighboring jurisdictions may exist.
Q4: How does this patent influence the competitive landscape?
It provides a legal monopoly in Russia over the specific formulation, encouraging competitors to explore alternative compositions or delivery methods.
Q5: What are the main legal risks associated with this patent?
Potential risks include overlapping claims by competitors and challenges based on prior art. Scrutinizing claim scope against existing patents in relevant regions is recommended.
References
- Russian Patent Office (Rospatent). (2023). Patent RU2724894.
- World Intellectual Property Organization (WIPO). (N/A). Patent family data.
- Russian Federation Patent Law. (2021).
- Patent landscape reports from IP attorneys specializing in Russian pharmaceuticals.
- Patent databases: Espacenet, WIPO PATENTSCOPE.
